SABCS

Clinically focused coverage from the American Society of Hematology (ASH) Annual Meeting, highlighting key data across malignant and nonmalignant hematologic disorders.

General Breast Cancer

View All

1. Hands holding a pink ribbon symbolizing breast cancer awareness on a gray background.

General Breast Cancer

01/17/2026

From ADCs to Oral SERDs: Practice-Changing Insights from SABCS 2025

Zunairah Shah, MD

HER2-Positive Breast Cancer

View All

Dr. Harold Burstein presenting at SABCS 2025 on four key HER2+ breast cancer trials, with images of Dr. Rahul Gosain and Dr. Rohit Gosain in the background.

HER2-Positive Breast Cancer

02/10/2026

4 Significant Trials for HER2+ Breast Cancer at SABCS 2025

Harold Burstein, MD, PhDRohit Gosain, MDRahul Gosain, MD, MBA

HER2-positive breast cancer research update featuring Yash Agrawal, MD, and Stephanie Graff, MD, discussing 2025 advancements in DESTINY trials and beyond for improved breast cancer therapies.

HER2-Positive Breast Cancer

01/05/2026

The Evolving Role of T-DXd Across HER2+ Breast Cancer

Yash Agrawal, MDStephanie Graff, MD, FACP, FASCO

1. Advanced biomarker-guided care in HER2-positive breast cancer using ctDNA, TILs, and HER2DX for personalized oncology treatment and improved patient outcomes.

HER2-Positive Breast Cancer

12/31/2025

Emerging Roles of Biomarkers in HER2-Positive Breast Cancer

Yash Agrawal, MDMadison Canning, MD

HER2-positive breast cancer updates from SABCS 2023, featuring expert Vaishali Deenadayalan at Roswell Park, emphasizing advancements in treatment and research in oncology for improved patient outcomes.

HER2-Positive Breast Cancer

12/30/2025

Updates in HER2-Positive Breast Cancer From SABCS 2025

Vaishali Deenadayalan, MD

1. Advanced breast cancer treatment strategies for early HER2-positive cases, featuring expert insights from MDs Ya Haddy Salah and Nerea Lopetegui.

HER2-Positive Breast Cancer

12/28/2025

De-escalation and Sequencing Strategies Shape HER2-Positive Breast Cancer Care at SABCS 2025

Nerea Lopetegui-Lia, MDYa Haddy Sallah, MD, MPH

1. Integrating Tucatinib and T-DXd for HER2-positive breast cancer treatment, across disease settings, to enhance targeted therapy effectiveness and patient outcomes.

HER2-Positive Breast Cancer

12/26/2025

SABCS 2025: HER2CLIMB-05 and DESTINY Trials Point to More Individualized Care in HER2-Positive Breast Cancer

Nerea Lopetegui-Lia, MDSusan Dent, BSc, MD

HER2-Positive Breast Cancer

12/19/2025

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MDVaishali Deenadayalan, MD

HR+ Disease

View All

Early morning view of a waterfront with a promotional banner for OncUpdates, featuring Dr. Hope Rugo and two other doctors discussing metastatic HR+ breast cancer highlights for SABCS 2025.

HR+ Disease

02/06/2026

HR+ Metastatic Breast Cancer Updates from SABCS 2025

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Inovative breast cancer research and treatment insights from OncUpdates, featuring experts Tyler Kristoff, MD, and Sarah Premji, MD, focusing on the role of Inavolisib as a first-line therapy and emerging oral SERDs.

HR+ Disease

01/13/2026

SABCS 2025 Updates on Inavolisib and Giredestrant in Breast Cancer

Tyler Kristoff, MDSarah Premji, MD

1. In-depth analysis of HR+ and early breast cancer studies from SABCS 2025 featuring experts Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Laura Huppert.

HR+ Disease

01/12/2026

Key HR+, Early Breast Cancer Abstracts From SABCS 2025

Laura Huppert, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Female healthcare professionals discussing breast cancer prevention and patient advocacy for cancer care education and empowerment.

HR+ Disease

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

Enhanced image of two medical professionals discussing CDK4/6 inhibitors for cancer treatment at OncUpdates, with a cityscape background highlighting expertise in oncology research and therapy options.

HR+ Disease

01/02/2026

NATALEE 5-Year IDFS Data at SABCS 2025

Matthew Kurian, MDJasmin Hundal, MD

1. Interpreting MONALEESA, NATALEE, and monarchE in clinical oncology practice, featuring healthcare professionals discussing advanced breast cancer treatments.

HR+ Disease

12/29/2025

SABCS 2025: Expert Perspective on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive Breast Cancer

Matthew Kurian, MDElia Segui Solis, MD

Innovative hormone receptor-positive breast cancer treatment paradigms discussed by Dr. Jasmin Hundal, expert from Cleveland Clinic, highlighting advancements and research updates in oncology.

HR+ Disease

12/27/2025

Shifting Treatment Paradigms in Hormone Receptor–Positive Breast Cancer

Jasmin Hundal, MD

Adjuvant CDK4/6 inhibition in early breast cancer discussed by renowned experts Matthew Kurian and Komal Jhaveri at OncUpdates.

HR+ Disease

12/21/2025

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACPMatthew Kurian, MD

1. Advances in early-stage breast cancer treatment focusing on CDK4/6 inhibitors for adjuvant therapy.

HR+ Disease

12/19/2025

Key Insights From the NATALEE Trial

Karissa Britten, MDMatthew Kurian, MD

1. AlT text: Expert discussion on managing breast cancer relapse with adjuvant CDK4/6 inhibitor therapy in ER-positive cases, featuring Dr. Sarah Premji and Dr. Kevin Kalinsky.

HR+ Disease

12/18/2025

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCOSarah Premji, MD

TNBC

View All

Dr. Rebecca Shatsky discusses clinical trials on adjuvant carboplatin and PARP inhibitors in triple-negative breast cancer (TNBC) at OncUpdates.

TNBC

03/05/2026

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert doctors Mariam Haji Ahmad and Alexis Levee discuss early use of first-line ADCs in breast cancer treatment and advancements in sequencing technology for improved patient outcomes.

TNBC

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

Antibody-drug conjugates reshaping triple-negative breast cancer treatment algorithm, oncologists discuss advances.

TNBC

01/15/2026

ADCs in TNBC: Current Data and Unanswered Questions

Pietro De Placido, MDDionisia Quiroga, DO, PhD

1. Expert discussion on TROP2 ADC options in PD-L1-negative TNBC featuring Alexis LeVee and Paolo Tarantino, MD.

TNBC

01/01/2026

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Alexis Levee, MDPaolo Tarantino, MD

Accelerating breast cancer treatment research by integrating Sacituzumab govitecan, Pembrolizumab, with expert clinicians Dionisia Quiroga, DO, PhD, and Erika Hamilton, MD, in Las Vegas skyline background.

TNBC

12/25/2025

SABCS 2025: Clarifying Where Sacituzumab Govitecan Fits in the Breast Cancer Treatment Landscape

Erika Hamilton, MD, FASCODionisia Quiroga, DO, PhD

Advances in early-stage and metastatic triple-negative breast cancer (TNBC) treatments, featuring expert insights from Dr. Briana To, highlighting evolving oncologic approaches and clinical research.

TNBC

12/19/2025

Evolving Approaches to Early-Stage and Metastatic TNBC

Briana To, DO, PhD